What is the clinical evidence from this study?

Study design: Other. Population: 心不全. Intervention: サクビトリルバルサルタン (ARNI) vs. エナラプリル 20 mg 1日2回. Primary outcome: 心血管死または心不全入院 (HR 0.80, 95% CI null, p=null).

What question did this study set out to answer?

To review recent updates in the treatment of heart failure categorized by ejection fraction.

March 13, 2026Open Access

2) Heart failure treatment update 2025

Key Result

サクビトリルバルサルタンは心血管死または心不全入院を20%低下させた。

Key Points

To review recent updates in the treatment of heart failure categorized by ejection fraction.
Analysis of heart failure categorization based on ejection fraction levels
Review of treatment protocols for HFrEF and HFmrEF
Evaluation of recent clinical guidelines
Updates on effective treatment options for those with HFrEF
New strategies for managing mildly reduced ejection fraction cases
Emphasis on personalized treatment approaches

PICO

Population

心不全

Intervention / Comparator

サクビトリルバルサルタン (ARNI) vs エナラプリル 20 mg 1日2回 (200 mg 1日2回)

Primary Outcome

心血管死または心不全入院 — HR 0.80 (null), p=null

Main Result

Effect estimate: HR 0.80 (95% CI null)

p-value: p=null

Abstract

Ventricular Ejection FractionLVEF) LVEF 40HFrEF(Heart Failure with reduced Ejection Fraction) LVEF 4149 HFmrEF(mildly reduced Ejection Frac-tion)

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Y. Sakata (Mon,) conducted a other in 心不全. サクビトリルバルサルタン (ARNI) vs. エナラプリル 20 mg 1日2回 was evaluated on 心血管死または心不全入院 (HR 0.80, 95% CI null, p=null). サクビトリルバルサルタンは心血管死または心不全入院を20%低下させた。.

synapsesocial.com/papers/69b3ab0002a1e69014ccbb31 https://doi.org/https://doi.org/10.2169/naika.114.338